Additionally, in the CAR2BRAIN Phase I clinical trial (NCT03383978, Table 1), researchers are evaluating HER2-specific CAR-NK-92/5.28z cells, in combination with the anti-PD-1 mAb Ezabenlimab, for patients with recurrent HER2-positive glioblastoma (51, 119). This evidence concerns the gene ERBB2 and glioblastoma.